UBS Group
VERA icon

UBS Group’s Vera Therapeutics VERA Stock Holding History

UBS Group’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.9M Buy
254,182
+66,295
+35% +$2.47M ﹤0.01% 3352
2026
Q1 		$7.56M Sell
187,887
-19,402
-9% -$836K ﹤0.01% 3639
2025
Q4 		$10.5M Buy
207,289
+45,214
+28% +$1.61M ﹤0.01% 3231
2025
Q3 		$4.71M Buy
162,075
+59,142
+57% +$1.37M ﹤0.01% 4103
2025
Q2 		$2.43M Sell
102,933
-356,734
-78% -$8.02M ﹤0.01% 4615
2025
Q1 		$11M Buy
459,667
+362,364
+372% +$11.6M ﹤0.01% 2930
2024
Q4 		$4.11M Buy
97,303
+14,929
+18% +$661K ﹤0.01% 4042
2024
Q3 		$3.64M Buy
82,374
+7,912
+11% +$300K ﹤0.01% 3391
2024
Q2 		$2.69M Sell
74,462
-51,921
-41% -$2.06M ﹤0.01% 3453
2024
Q1 		$5.45M Buy
126,383
+10,961
+9% +$391K ﹤0.01% 2884
2023
Q4 		$1.78M Buy
115,422
+71,487
+163% +$908K ﹤0.01% 3959
2023
Q3 		$602K Buy
43,935
+23,202
+112% +$398K ﹤0.01% 4514
2023
Q2 		$333K Buy
20,733
+11,800
+132% +$107K ﹤0.01% 5146
2023
Q1 		$69.3K Buy
8,933
+8,036
+896% +$62K ﹤0.01% 6184
2022
Q4 		$17.4K Sell
897
-4,401
-83% -$79.7K ﹤0.01% 7840
2022
Q3 		$113K Buy
5,298
+4,903
+1,241% +$91.8K ﹤0.01% 5609
2022
Q2 		$5K Sell
395
-1,614
-80% -$28.2K ﹤0.01% 8942
2022
Q1 		$47K Buy
+2,009
New +$43.2K ﹤0.01% 6565
2021
Q3 		– Sell
-956
Closed -$13K – 10121
2021
Q2 		$13K Buy
+956
New +$14.9K ﹤0.01% 7810

Other funds holding VERA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS Group's VERA Position: Q2 2026 in Review

UBS Group increased its Vera Therapeutics (VERA) stake by 35% in Q2 2026, buying an estimated $2.47M and bringing the position to 254,182 shares worth $10.9M. The position accounts for ﹤0.01% of the portfolio, ranked #3352.

UBS Group first reported a position in VERA in Q2 2021 and has held it in 19 quarters since. The position peaked at $11M in Q1 2025. 219 funds tracked by Wall St. Rank hold VERA as of Q2 2026.

  • UBS Group held 254,182 shares of Vera Therapeutics worth $10.9M as of Q2 2026.
  • UBS Group bought 66,295 Vera Therapeutics shares in Q2 2026, an estimated $2.47M.
  • Vera Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #3352 holding.
  • UBS Group first reported a position in Vera Therapeutics in Q2 2021 and has held it in 19 quarters since.
  • UBS Group's Vera Therapeutics position peaked at $11M in Q1 2025.
  • 219 funds tracked by Wall St. Rank held Vera Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.